Despite its successes, the PCGP faces several challenges. One major hurdle is the complexity of cancer genomes, which often contain a myriad of genetic alterations that can be difficult to interpret. Additionally, while significant progress has been made in identifying mutations, translating these findings into clinical applications remains a lengthy and complex process. The project also requires substantial financial and technical resources, which can be a limiting factor.
